Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -117.98% is 64% below its 5-year average of -72.01%, around the middle of its 5-year range (-181.80%–-32.32%).
As of the fiscal period ended Tuesday, June 30, 2026. 26.25% below its 12-month average of -93.44%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -117.98%.
RETURN ON EQUITY (ROE)
-117.98%
RETURN ON EQUITY (ROE) AVG TTM
-93.44%
RETURN ON EQUITY (ROE) AVG 3Y
-64.62%
RETURN ON EQUITY (ROE) AVG 5Y
-72.01%
RETURN ON EQUITY (ROE) AVG 10Y
-71.77%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-26.25%
CURRENT VS 3Y AVG
-82.56%
CURRENT VS 5Y AVG
-63.82%
CURRENT VS 10Y AVG
-64.37%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.51%
median of 487 covered companies
CURRENT VS SECTOR MEDIAN
-206.35%
vs the sector median at left
Cosmos Health Inc.
Market Cap
$19.02M
Return on Equity (ROE)
-117.98%
TTM Avg
-93.44%
3Y Avg
-64.62%
5Y Avg
-72.01%
Market Cap
$19.42M
Return on Equity (ROE)
N/A
TTM Avg
-3014.83%
3Y Avg
-1589.49%
5Y Avg
-1032.64%
Market Cap
$19.50M
Return on Equity (ROE)
-2067.81%
TTM Avg
-13234.78%
3Y Avg
-6645.16%
5Y Avg
-6645.16%
Market Cap
$16.87M
Return on Equity (ROE)
N/A
TTM Avg
-416.37%
3Y Avg
-259.03%
5Y Avg
-190.00%
Market Cap
$17.19M
Return on Equity (ROE)
-54.45%
TTM Avg
-33.23%
3Y Avg
-44.23%
5Y Avg
-52.50%
Market Cap
$16.74M
Return on Equity (ROE)
-101.76%
TTM Avg
-188.04%
3Y Avg
-167.76%
5Y Avg
-134.95%
Market Cap
$16.43M
Return on Equity (ROE)
-271.81%
TTM Avg
-934.34%
3Y Avg
-347.56%
5Y Avg
-265.02%
Market Cap
$22.22M
Return on Equity (ROE)
-40.40%
TTM Avg
-55.95%
3Y Avg
-53.10%
5Y Avg
-83.38%
Market Cap
$15.75M
Return on Equity (ROE)
-348.81%
TTM Avg
-160.92%
3Y Avg
-184.71%
5Y Avg
-151.29%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cosmos Health Inc. (COSM) | $19.02M | -117.98% | -93.44% | -64.62% | -72.01% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $19.42M | N/A | -3014.83% | -1589.49% | -1032.64% |
| Actuate Therapeutics Inc (ACTU)vs › | $19.50M | -2067.81% | -13234.78% | -6645.16% | -6645.16% |
| Dyadic International, Inc. (DYAI)vs › | $16.87M | N/A | -416.37% | -259.03% | -190.00% |
| Lipocine Inc. (LPCN)vs › | $17.19M | -54.45% | -33.23% | -44.23% | -52.50% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.74M | -101.76% | -188.04% | -167.76% | -134.95% |
| BioCardia, Inc. (BCDA)vs › | $16.43M | -271.81% | -934.34% | -347.56% | -265.02% |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.22M | -40.40% | -55.95% | -53.10% | -83.38% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.75M | -348.81% | -160.92% | -184.71% | -151.29% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.44M | -951.92% | -161.65% | -122.41% | -87.71% |
ROE
-118.0%
ROA
-39.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -117.98% |
| 2026-03-31 | -106.59% |
| 2025-12-31 | -103.91% |
| 2025-09-30 | -80.15% |
| 2025-06-30 | -58.60% |
| 2025-03-31 | -58.32% |
| 2024-12-31 | -65.96% |
| 2024-09-30 | -58.30% |
| 2024-06-30 | -67.12% |
| 2024-03-31 | -57.75% |
| 2023-12-31 | -51.45% |
| 2023-09-30 | -35.03% |
| 2023-06-30 | -32.32% |
| 2023-03-31 | -32.66% |
| 2022-12-31 | -34.88% |
| 2022-09-30 | -86.95% |
| 2022-06-30 | -54.53% |
| 2022-03-31 | -108.41% |
| 2021-12-31 | -181.80% |
| 2021-09-30 | -157.40% |
| 2018-09-30 | -67.22% |
| 2015-09-30 | -12.36% |
| 2015-06-30 | 88.57% |
| 2015-03-31 | 110.79% |
| 2014-12-31 | 110.43% |
| 2014-09-30 | 124.89% |
| 2014-06-30 | 160.09% |
